ESMO Conference Coverage
Filter News By:
Featured News
View all
More News
(Yahoo! Finance) Oct 9, 2019 - Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone. MONARCH 2 showed statistically significant results for women whose disease...
(Yahoo! Finance) Oct 8, 2019 - Adlai Nortye Ltd. announced today at the European Society for Medical Oncology (ESMO) 2019 Congress the first results from a phase 1b neoadjuvant study of AN0025 (previously known as E7046), an...
(Vantage) Oct 2, 2019 - An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the...
(CNN) Sept 30, 2019 - An experimental prostate cancer therapy may change the way patients are treated for the second-deadliest cancer in men. In a "landmark" phase III clinical trial, presented at the European Society of Medical...
(Precision Oncology News) Sept 29, 2019 - In presentations at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, researchers reported seemingly contradictory results on the utility of tumor mutational...
(Xconomy National) Oct 1, 2019 - The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few...
(Precision Oncology News) Sept 30, 2019 - Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor...
(Elevar Therapeutics) Sept 29, 2019 - Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal...
(Markets Insider) Sept 30, 2019 - The Alliance for Safe Biologic Medicines (ASBM) this week shared preliminary findings from a survey of 575 biologic prescribers in six Western European countries, covering several key policy issues...
Expert Videos

OBR Tweets

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S

Aug 25
At the ASCO20 Virtual Education Program, Nilanjan Ghosh, MD, PhD, a hematologist-oncologist at the @LevineCancer, p… https://t.co/o2s69MGfrW

Aug 25
At the #ASCO20 Virtual Education Program, Jaleh Fallah @Jaleh_Fallah, MD, a Hematology/Oncology Fellow at the Cleve… https://t.co/QDkyebDuvp

Aug 25
The financial toxicity that patients and oncology practices are potentially exposed to due to the high costs associ… https://t.co/QA8A13PAGT

Aug 25
At separate #AACR and #COA virtual meetings held in July, participants discussed the challenges of providing cancer… https://t.co/8fs8SKl65a